首页> 外文期刊>Genetic Testing >Detection of Somatic Mutations and Germline Polymorphisms in Mitochondrial DNA of Uterine Fibroids Patients
【24h】

Detection of Somatic Mutations and Germline Polymorphisms in Mitochondrial DNA of Uterine Fibroids Patients

机译:子宫肌瘤患者线粒体DNA体细胞突变和种系多态性的检测

获取原文
获取原文并翻译 | 示例
           

摘要

To identify the role of mitochondrial DNA (mtDNA) mutations in uterine fibroids patients, genomic DNA isolated from paired myometrium and fibroid tissues was screened for mutations. The present study represents the first investigation to report that 10.4% of uterine fibroids cases had either mtDNA mutations or polymorphisms or both. Among the 14 mitochondrial sequence variants identified, seven are somatic mutations (A3327C, G3352A, G3376A, G3380A, G3421A, T15312G, and C15493G) and the remaining (G3316A, C3342A, C3442T, T10205A, A10188G, A10229C, and A10301T) are gene polymorphisms. Somatic mutations were both homo- and heteroplasmic in nature. Of the seven somatic mutations located in the MTND1 and MTCYB genes, five (71.42%) are nonsynonymous in nature, whereas four (57.14%) of the polymorphisms located in MTND1 and MTND3 genes are found to be nonsynonymous. Sequence variants such as G3380A, G3421A, T15312G, G3376A, and G3316A have been earlier described in different human pathologies, but the remaining are novel ones. Mitochondrial somatic mutations and polymorphisms may predispose women to an earlier onset of degenerative cellular processes, which impair oxidative phosphorylation capacity and thereby promote tu-morigenesis in uterine smooth muscle cells. Detection of mtDNA sequence variations in fibroid patients raises the need for larger case-control studies to screen the whole mitochondrial genome and evaluate as a future diagnostic biomarker in fibroid patients.%Department of Genetics and Molecular Medicine, Vasavi Medical and Research Centre, Hyderabad, India,Research Chair of Medical and Molecular Genetics, Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, Riyadh, Kingdom of Saudi Arabia;Department of Genetics, University College of Science, Osmania University, Hyderabad, India,Department of Genetics and Molecular Medicine, Kamineni Hospitals, Hyderabad, India;Department of Genetics, University College of Science, Osmania University, Hyderabad, India,Department of Genetics and Molecular Medicine, Kamineni Hospitals, Hyderabad, India;Department of Genetics and Molecular Medicine, Vasavi Medical and Research Centre, Hyderabad, India,Department of Genetics, University College of Science, Osmania University, Hyderabad, India;Department of Genetics, University College of Science, Osmania University, Hyderabad, India;Department of Genetics and Molecular Medicine, Vasavi Medical and Research Centre, Hyderabad, India;Department of Genetics and Molecular Medicine, Vasavi Medical and Research Centre, Hyderabad, India,Department of Genetics and Molecular Medicine, Kamineni Hospitals, Hyderabad, India;
机译:为了确定线粒体DNA(mtDNA)突变在子宫肌瘤患者中的作用,从配对的子宫肌层和肌瘤组织中分离的基因组DNA进行了突变筛选。本研究是第一个报告称有10.4%子宫肌瘤病例具有mtDNA突变或多态性或两者兼有的调查。在确定的14个线粒体序列变体中,有7个是体细胞突变(A3327C,G3352A,G3376A,G3380A,G3421A,T15312G和C15493G),其余(G3316A,C3342A,C3442T,T10205A,A10188G,A10229C和A10301T是基因) 。体细胞突变本质上是同质和异质的。在MTND1和MTCYB基因中的七个体细胞突变中,有五个(71.42%)本质上是非同义的,而在MTND1和MTND3基因中有四个(57.14%)多态性是不同义的。诸如G3380A,G3421A,T15312G,G3376A和G3316A之类的序列变体已在不同的人类病理学中进行了较早的描述,但其余都是新颖的。线粒体体细胞突变和多态性可能会使女性更早地发生变性细胞过程,从而损害氧化磷酸化能力,从而促进子宫平滑肌细胞的成瘤。检测肌瘤患者的mtDNA序列变异,因此需要进行更大的病例对照研究,以筛选整个线粒体基因组,并评估其作为肌瘤患者的未来诊断生物标志物。海得拉巴Vasavi医学与研究中心遗传与分子医学系印度,沙特阿拉伯利雅得金沙特大学,应用医学科学学院,医学和分子遗传学,临床实验室科学系,沙特阿拉伯利雅得;遗传学系,奥斯曼尼亚大学科学学院,印度海得拉巴,系印度海得拉巴Kamineni医院遗传与分子医学系;印度奥斯曼尼亚大学科学学院遗传学系,印度海得拉巴印度海得拉巴Kamineni医院遗传与分子医学系;印度海得拉巴遗传与分子医学系印度海得拉巴Vasavi医学与研究中心,科学大学遗传学系印度海得拉巴的奥斯曼尼亚大学ience;印度海得拉巴的奥斯曼尼亚大学理学院大学遗传学系;印度海得拉巴Vasavi医学和研究中心遗传与分子医学系;印度海得拉巴遗传与分子医学系印度海得拉巴医学和研究中心,印度海得拉巴Kamineni医院遗传与分子医学系;

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号